A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Trial ID or NCT#

NCT01732822

Status

not recruiting iconNOT RECRUITING

Purpose

The purpose of this study is to compare the effects of ticagrelor and clopidogrel in patients with Peripheral Artery Disease.

Official Title

A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease (EUCLID Examining Use of tiCagreLor In paD)

Eligibility Criteria

Ages Eligible for Study: 50 Years to 130 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. * Male and Female patients 50 years old or older Symptomatic peripheral artery disease
Exclusion Criteria:
  1. * Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation* Patients with known bleeding disorders* Patients with a history of intracranial bleed* Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker
View All Criteria
Show Less

Contact us to find out if this trial is right for you.

Contact

AstraZeneca Clinical Study Information
800-236-9933

View on ClinicalTrials.gov